Medical Cannabis Studies

• View All (505)

Cannabinoid receptor CB1-like and glutamic acid decarboxylase-like immunoreactivities in the brain of Xenopus laevis (2001)

In this investigation, the CB1 receptor distribution of cannabinoids was investigated in the brain of Xenopus laevis (anuran amphibians) by immunohistochemistry, using light and confocal laser scanning microscopy. It was demonstrated that the distribution of CB1 remains in the course of phylogeny. View study
Cannabinoid receptor ligands as potential anticancer agents � high hopes for new therapies (2009)

It is possible that cannabinoids have anticancer effects in the appropriate context, although their effects may not be significant enough for chemotherapy. Future studies will be able to demonstrate whether cannabinoids or cannabimimetic agents have the ability to reduce tumor growth in vivo synergistically with chemotherapeutic agents. View study
Cannabinoid Receptor Type 2, but not Type 1, is Up-Regulated in Peripheral Blood Mononuclear Cells of Children Affected by Autistic Disorders (2013)

At present there is no absolutely effective treatment for autism, in fact the curative therapy is very difficult. These studies reflect the cannabinoid receptor CB2 as a possibility for the therapy and pharmacological management of autism. View study
Cannabinoid Receptor-Mediated Apoptosis Induced by R()-Methanandamide and Win55,212-2 Is Associated with Ceramide Accumulation and p38 Activation in Mantle Cell Lymphoma (2006)

The CB1 and CB2 receptors may have a great therapeutic potential for the treatment of mantle cell lymphoma. View study
Cannabinoid Receptors and Endocannabinoids: Evidence for New Players (2006)

In this research we study the evidence that shows that cannabinoids can modulate synaptic transmission, the cardiovascular system and the immune system through receptors other than CB1 and CB2. View study
Cannabinoid receptors and their ligands (2002)

This research focused on the study of cannabinoid receptors and their ligands. The discovery of the system of cannabinoid and endocannabinoid receptors that form the endocannabinoid system has stimulated the development of selective agonists and antagonists of CB1 and CB2. Reverse agonists. The CB1 / CB2 agonists are already used clinically, as antiemetics or to stimulate the appetite. Possible therapeutic uses of cannabinoid receptor agonists include the treatment of multiple sclerosis / spinal cord injury, pain, inflammatory disorders, glaucoma, bronchial asthma, vasodilation that accompanies advanced cirrhosis and cancer. View study
Cannabinoid receptors as novel targets for the treatment of melanoma (2006)

The activation of cannabinoid receptors CB1 and CB2 succeeded in reducing the growth, proliferation, angiogenesis and metastasis, and the increase of apoptosis, of melanomas in mice. This discovery may contribute to the design of new chemotherapeutic strategies for the treatment of melanoma. View study
Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain (2011)

Using brain from rats this research focused on the study of the role of CB2 cannabinoid receptors in the brain, we present evidence of the molecular and functional interaction of the CB2 receptor with CB1 cannabinoid receptors. The data obtained in this study show the mechanism by which CB2 receptors can negatively modulate CB1 receptor function. View study
Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis (2011)

The cannabinoid receptors CB1 and CB2 have the potential to become therapeutic targets against non-small cell lung cancer. In this study it was demonstrated that the treatment of cell lines of this type of cancer with CB1 / CB2 and CB2-specific agonists Win55, 212-2 and JWH-015 significantly reduced both the growth factor-directed in vitro chemotaxis and chemoinvasion in these cells. View study
Cannabinoid Regulation of Acute and Anticipatory Nausea (2016)

In this research we review the human and preclinical literature in animals that analyzes the potential of exogenous and endogenous cannabinoid treatments to regulate the nausea produced by chemotherapy. View study
Cannabinoid system and cyclooxygenases inhibitors (2011)

This research focuses its study on summarizing the existing data on the interactions of the nonsteroidal anti-inflammatory drugs NSAIDS-cannabinoids system. It was concluded that some NSAIDs have additional influences on the cannabinoid system either by inhibiting the hydrolase of fatty acid amides (FAAH) or by inhibiting a possible intracellular endocannabinoid transporter. View study
Cannabinoid Type 2 Receptors Mediate a Cell Type Specific Plasticity in the Hippocampus (2016)

In this study we describe a mechanism of cell-specific plasticity in the hippocampus that provides evidence of the neuronal expression of cannabinoid type 2 receptors (CB2R) and emphasizes its importance in basic neuronal transmission. View study